Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension

• Main Authors: Alexandra B. Kimball (Author), Thomas Luger (Author), Alice Gottlieb (Author), Luis Puig (Author), Roland Kaufmann (Author), Russel Burge (Author), Chen-Yen Lin (Author), Gil Yosipovitch (Author)
• Format: Book
• Published: Medical Journals Sweden, 2017-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Itching is a prevalent plaque psoriasis symptom. Ixekizumab, an IL-17A antagonist, has demonstrated rapid, significant improvements in itch severity over 12 weeks in Phase III psoriasis trials (UNCOVER-1, UNCOVER-2). We assessed the long-term (through 60 weeks) effect of ixekizumab maintenance thera...